A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 3, 1996, Pages 221-232

  Cotropia, Joseph ^a,b   Ugen, Kenneth E ^c,e   Kliks, Srisakul ^d   Broliden, Kristina ^c,e   Broliden, Per Anders ^c,e   Hoxie, James A ^a   Srikantan, Vasantha ^a   Williams, William V ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BioClonetics Inc   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Active immunotherapy; Conserved envelope epitope; HIV 1 passive immunotherapy; Human monoclonal antibody; Neutralization

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYBRIDOMA; IMMUNOBLOTTING; IMMUNOTHERAPY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

EID: 0030035109     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199607000-00002     Document Type: Article

References (64)

1. Broliden P-A, von Gegerfelt A, Clapham P, et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992;89:461-5.
2. Goodenow M, Surin W, Huet T, Kwok S, Sninksy J, WainHobson S. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred molecular substitutions. J AIDS 1989;2:344-52.
3. Wolfs TFW, Nara PL, Goudsmit J. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination. In: Norrby E, ed. Immunochemistry of AIDS. Basel: S. Karger AG, 1993:1-33.
4. Robert-Guroff M, Brown M, Gallo RC. HTLV-III neutralizing antibodies in patients with AIDS and AIDS related complex. Nature 1985;316:72-4.
5. Rasheed S, Norman GL, Gill PS, Meyer PR, Cheng L, Levine A. Virus-neutralizing activity, serologic heterogeneity and retrovirus isolation from homosexual men in the Los Angeles area. Virology 1986;150:1-9.
6. Robert-Guroff M, Goedert JJ, Naugle CJ, Jennings AM, Blattner WA, Gallo RC. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. AIDS Res Hum Retroviruses 1988;4:343-50.
7. Schafferman A, Lennox J, Grosfeld H, Sadoff J, Redfield RR, Burke DS. Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope of sera from different stages of HIV infection. AIDS Res Hum Retroviruses 1989;5:33-9.
8. Chiodi F, von Gegerfeldt A, Albert J, et al. Site-directed ELISA with synthetic peptides representing the HIV transmembrane glycoprotein. J Med Virol 1987;23:1-9.
9. McPhee DA, Kemp BE, Cumming S, Stapleton D, Gust ID, Doherty RR. Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett 1988;233:393-6.
10. D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, Milan G. Collaborating Investigators. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration. AIDS 1994;8;169-81.
11. Gnann JW, Schwimmbeck PL, Nelson JA, Truax AB, Oldstone MBA. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis 1987;156:261-7.
12. Schrier RD, Gnann JW, Langlois AJ, Shriver K, Nelson JA, Oldstone MBA. B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus. J Virol 1988;62:2531-6.
13. Klasse PJ, Pipkorn R, Blomberg J. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proc Natl Acad Sci USA 1988;85:5225-9.
14. Goudsmit J, Meloen RH, Brasseur R. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 1990;31:327-38.
15. Horal P, Svennerholm B, Jeansson S, Rymo L, Hall WW, Vahlne A. Continuous epitopes of the human immunodeficiency virus type I (HIV-I) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates. J Virol 1991;65:2718-23.
16. Vanini S, Longhi R, Lazzarin A, Vigo E, Siccardi AG, Viale G. Discrete regions of HIV-1 gp41 defined by syncytiainhibiting affinity-purified human antibodies. AIDS 1993;7: 167-74.
17. Ugen KE, Goedert JJ, Boyer J, et al. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 1992;89:1923-30.
18. Ugen KE, Wang B, Ziegner U, et al. Vertical transmission of human retroviral infections. Immunological considerations. Arch STD HIV Res 1994;8:283-92.
19. Rossi P, Moschese V, Broliden PA, et al. Presence of antibodies to HIV-1 gp120 env epitopes correlates with the uninfected status of the children born to seropositive mothers. Proc Natl Acad Sci USA 1989;86:8055-8.
20. Goedert JJ, Mendez H, Drummond JE, et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet 1989;2:1351-4.
21. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci USA 1990;87:3445-9.
22. Tyler DS, Stanley SD, Zolla-Pazner S, et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol 1990;145:3276-82.
23. Banapour B, Rosenthal K, Rabin L, et al. Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus. J Immunol 1987;139:4027-33.
24. Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci USA 1989;86:1624-8.
25. Xu J-Y, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991;65:4832-8.
26. Bugge TH, Lindhardt BO, Hansen LL, et al. Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody. J Virol 1990;64: 4123-9.
27. Teeuwsen VJ, Siebelink KH, Crush-Stanton S, et al. Production and characterization of human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1990;6:381-92.
28. Grunow R, Jahn S, Porstmann T, et al. The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods 1988;106:257-65.
29. Ohlin M, Broliden PA, Danielsson L, et al. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Immunology 1989;68:325-31.
30. Pollock BJ, McKenzie AS, Kemp BE, McPhee DA, D'Apice AJ. Human monoclonal antibodies to HIV-1: cross-reactions with gag and env proteins. Clin Exp Immunol 1989; 78:323-8.
31. Sugano T, Masuho Y, Matsumoto Y, et al. Human monoclonal antibody against glycoproteins of human immunodeficiency. Biochem Biophys Res Commun 1988;155:1105-12.
32. Prigent S, Goossens D, Clerget-Raslain B, et al. Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1. AIDS 1990;4:11-19.
33. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-7.
34. Eaton AM, Ugen KE, Weiner DB, Wildes T, Levy JA. An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Res Hum Retroviruses 1994;10:13-18.
35. Nixon DF, Broliden K, Ogg G, Broliden P-A [Editorial review]. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992;76:515-34.
36. Zolla-Pazner S, Gorny MK. Passive immunization for the prevention and treatment of HIV infection. AIDS 1992;6: 1235-47.
37. Schroff R, Foon K, Beatty S, Oldham R, Morgan A. Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-85.
38. Amadori A, Zamarchi R, Cimanale V, et al. HIV-1-specific B-cell activation: a major constituent of spontaneous B-cell activation during HIV-1 infection. J Immunol 1989;143: 2146-52.
39. Bartal AH, Hirshaut Y. Use of heteromyelomas in the enhancement of human monoclonal antibody production. In: Bartal AH, Hirshaut Y, eds. Methods of hybridoma formation. Clifton, New Jersey: Humana Press, 1987:257-71.
40. Cotropia J, Ugen KE, Lambert D, et al. Characterization of human monoclonal antibodies to the HIV-1 transmembrane gp41 protein. In: Brown F, Chanock RM, Ginsberg HS, Lerner RA, eds. Vaccines 92: Modern approaches to new vaccines including prevention of AIDS. New York: Cold Spring Harbor Laboratory, 1992:157-63.
41. Pan L-Z, Cheng-Mayer C, Levy JA. Patterns of antibody response in individuals infected with the human immunodeficiency virus? J Infect Dis 1987;155:626-32.
42. Hamilton RB, Wilson RW, Spillman T, Roebber M. Monoclonal antibody-based immunoenzymetric assays for quantification of human IgG and its four subclasses. J Immunoassay 1988;9:275-96.
43. Ratner L, Haseltine W, Livak KJ, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985;313: 277-84.
44. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 1985;82:5131-5.
45. Srikantan V, Wang B, Satre MA, et al. Cloning and biological characterization of human single-chain Fv fragments that mediate neutralization of HIV-1. AIDS 1994;8:1525-32.
46. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene 1938;27:493-7.
47. Dulbecco R. The nature of viruses. In: Virology. 2nd ed. Philadelphia: JP Lippincott, 1988:22-5.
48. Nara PL. Quantitative infectivity syncytium-forming microassay. In: Aldovini A, Walker BD, eds. Techniques in HIV Research. New York: Stockton, 1989:77-86.
49. Montifiori DC, Robinson WE, Schiffman SS, Michell WM. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;6:231-5.
50. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 1990;64:1437-40.
51. Cheng-Mayer C, Homsy J, Evans LA, Levy JA. Identification of human immunodeficiency virus subtypes with direct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci USA 1988;85:2815-19.
52. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, Hendry RM, and Collaborating Investigators. Neutralization of primary HIV-1 isolates by anti-envelop monoclonal antibodies. AIDS 1995;9:867-74.
53. Jungbauer A, Tauer C, Wenisch E, et al. Pilot scale production of a human monoclonal antibody against human immunodeficiency virus HIV-1. J Biochem Biophys Methods 1989;19:223-40.
54. Weiss RA, Clapham PR, Cheingsong-Popov R, et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985;316:69-72.
55. Ho D, Sarngadharan MG, Hirsch MS, et al. Human immunodeficiency virus-neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol 1987;61:2024-8.
56. Rook AH, Lane HC, Folks T, McCoy S, Alter H, Fauci AS. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infectetf T cells. J Immunol 1987;138: 1064-7.
57. Ljunggren K, Böttiger B, Biberfeld G, Karlsson A, Fenyö E-M, Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol 1987;139: 2263-7.
58. Ojo-Amaize EA, Nishanian P, Keith JDE, et al. Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus infected cells. J Immunol 1987;139:2458-63.
59. Blumberg RS, Paradis T, Hartshorn KL, et al. Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus. J Infect Dis 1987; 156:878-84.
60. Shepp DH, Chakrabarti S, Moss B, Quinnan GV. Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. J Infect Dis 1988; 157:126-4.
61. Mitov IG, Terziiski DG. Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides. Infection 1991;6:383-96.
62. Broliden PA, Moschese V, Ljunggren K, et al. Diagnostic implication of specific immunoglobulin G patterns of children born to HIV-infected mothers. AIDS 1989;3:577-82.
63. Robinson WE, Kawamura T, Lake D, Masuho Y, Mitchell WM, Hersh EM. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 1990;64:5301-5.
64. Robinson WE, Gorny MK, Xu J-Y, Mitchell WM, ZollaPazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 (HIV-1) in vitro. J Virol 1991;65:4169-76.